SCHEMBL5860112

SCHEMBL5860112

CCC(=O)c1ccnc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.44
TAS1R1 Q7RTX1 2/20 0.44
TAS1R2 Q8TE23 2/20 0.44
RECQL P46063 1/20 0.44
SMARCA2 P51531 2/20 0.41
SMARCA4 P51532 2/20 0.41
ATM Q13315 1/20 0.41
LOX P28300 1/20 0.40
LOXL3 P58215 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PROKR1 Q8TCW9 1/20 0.39
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
CYP11B1 P15538 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4101750 0.83 GSK3B (0.48) TAS1R3TAS1R1TAS1R2RECQLSMARCA2
SCHEMBL30866516 0.83 GSK3B (0.48) TAS1R3TAS1R1TAS1R2RECQLSMARCA2
SCHEMBL7220421 0.82 TAS1R3 (0.49) TAS1R3TAS1R1TAS1R2RECQLSMARCA2
SCHEMBL1886203 0.81 GSK3B (0.50) TAS1R3TAS1R1TAS1R2RECQLSMARCA2
SCHEMBL29740122 0.81 GSK3B (0.50) TAS1R3TAS1R1TAS1R2RECQLSMARCA2
SCHEMBL12807872 0.81 RECQL (0.44) TAS1R3TAS1R1TAS1R2RECQLSMARCA2
SCHEMBL6504215 0.81 LOX (0.48) TAS1R3TAS1R1TAS1R2RECQLSMARCA2
SCHEMBL30953256 0.81 KDM4E (0.42) TAS1R3TAS1R1TAS1R2RECQLSMARCA2
SCHEMBL1988561 0.81 KDM4E (0.49) TAS1R3TAS1R1TAS1R2RECQLSMARCA2
Bromide SCHEMBL3610950 0.80 GSK3B (0.48) TAS1R3TAS1R1TAS1R2RECQLSMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024044730-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 WO disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 US disclosed
CN-104136431-A PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS ONO PHARMACEUTICAL CO 2014-11-05 CN disclosed
CN-103965161-A Substituted 2-aminopyridine inhibitor for protein kinase CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD 2014-08-06 CN disclosed
CN-103965168-A Aryl/heteroaryl-substituted 2-aminopyridine inhibitor for protein kinase CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD 2014-08-06 CN disclosed
CN-103508961-A Antitumor drug CROWN BIOSCIENCE TAICANG CO LTD 2014-01-15 CN disclosed
CN-101410387-B Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene-and furan-derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2013-12-18 CN disclosed
CN-103153945-A 1-oximino-3-phenyl-propanes HOFFMANN LA ROCHE 2013-06-12 CN disclosed
CN-101312965-B Morpholine type cinnamamide compound EISAI R&D MAN CO LTD 2011-07-20 CN disclosed
WO-2011045344-A1 PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT PIERRE FABRE MEDICAMENT (FR) 2011-04-21 WO disclosed
CN-1241192-A Pro-drugs and counterparts of camptothecin, their application as medicines SOD CONSEILS RECH APPLIC (FR) 2000-01-12 CN disclosed
CN-1241191-A Novel analogues of camptothecin, their use as medicaments and pharmaceutical compositions containing them SOD CONSEILS RECH APPLIC (FR) 2000-01-12 CN disclosed
US-5981542-A TOPOISOMERASE INHIBITORS; ANTITUMORAL DRUGS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1999-11-09 US disclosed
EP-0946567-A1 NOVEL COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1999-10-06 EP disclosed
EP-0946566-A1 PRO-DRUGS AND COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1999-10-06 EP disclosed
CN-1192740-A Novel camptothecin analogues, their preparation method, their pharmaceutical use and their pharmaceutical compositions SOD CONSEILS RECH APPLIC (FR) 1998-09-09 CN disclosed
WO-1998028304-A1 PRO-DRUGS AND COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1998-07-02 WO disclosed
WO-1998028305-A1 NOVEL COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1998-07-02 WO disclosed
EP-0835258-A1 NOVEL CAMPTOTHECIN ANALOGUES, PREPARATION METHODS THEREFOR, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID ANALOGUES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 1998-04-15 EP disclosed
WO-1997000876-A1 NOVEL CAMPTOTHECIN ANALOGUES, PREPARATION METHODS THEREFOR, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID ANALOGUES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) 1997-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159773-A1 HETEROCYCLIC COMPOUND TYK2, SSB, UACA TAS1R3 651/4885TAS1R1 469/4885TAS1R2 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.